Equity Overview
Price & Market Data
Price: $0.104
Daily Change: +$0.00635 / 6.13%
Range: $0.0973 - $0.11
Market Cap: $4,527,142
Volume: 336,867
Performance Metrics
1 Week: -4.05%
1 Month: 5.55%
3 Months: -98.33%
6 Months: -98.33%
1 Year: -98.33%
YTD: -51.00%
Company Details
Employees: 30
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease, which is in Phase 3 clinical trial; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. Palatin Technologies, Inc. was founded in 1986 and is based in Cranbury, New Jersey.